The Global Protein Therapeutics Market: Market Dynamics and Pipeline Analysis

The Global Protein Therapeutics Market: Market Dynamics and Pipeline Analysis

The global protein therapeutics market was valued at US$57 billion in 2005. Biotechnology has made notable inroads in the field of protein therapeutics, resulting in some of the key products presently available in the category. Recombinant proteins are potentially advantageous in terms of higher efficacy and fewer side effects than other pharmaceutical products, as they can be more specifically targeted to the cause of the disease, rather than the treatment of its symptoms.

This report examines each of the protein therapeutics classes in turn, assessing the market potential, and encompassing main therapeutic areas to which they are applicable.

The following product classes are analyzed in this report:

• erythropoietins (EPO)
• interferons
• interleukins
• insulin
• monoclonal antibodies
• blood-clotting factors
• colony-stimulating factors (CSFs)
• growth hormones
• plasminogen activators
• reproductive hormones
• therapeutic enzymes

The report assesses the overall protein therapeutics market, key classes, and the factors influencing their historical and future performance. The report provides an overview of key products in each category, comparing their clinical efficacy and marketing position. The overview of the current market is given in terms of segmentation by category, by region and by leading players and their products. Moreover, the report examines the promise of new drugs in each class and research and development efforts aimed at improving their delivery.

Finally, the future performance of the protein therapeutics market as a whole is examined against the background of pricing, emerging generic competition and manufacturing issues, indicating the likely trends in the coming years, and identifying possible solutions for problematic issues.

Key Features of this report:

• Overview of the protein therapeutics environment, including main therapeutic categories, drug delivery technologies and key players
• In-depth analysis of different classes of protein therapeutics, including key drugs in major therapeutic areas, as well as their advantages and disadvantages
• Comprehensive facts and figures for the protein therapeutics market, including main players and regional break-downs
• Future trends in the protein therapeutics marketplace, shaped by medical and technological advances as well as demographic and epidemiological changes and industry needs
• Outlook for the protein therapeutics market, including manufacturing considerations and research into new methods of protein delivery

Who should buy this report?

• Companies with a need to understand the protein therapeutics market and its place in the modern pharmaceutical industry
• Companies interested in understanding the impact and implications of product placement, lifecycle management and competition in the protein therapeutics marketplace
• Companies interested in understanding future opportunities in the protein therapeutics sector provided by a combination of factors, including changing demographics and financial issues
• Pharma/biotech companies wishing to identify potential protein therapeutics areas for partnerships and collaboration in order to examine a variety of profit maximization strategies

 
 

Table of Contents

1 Methodology, Executive Summary and Overview
• 1.1 Report Objectives
• 1.2 Research Methodology
• 1.3 Executive Summary
o 1.3.1 An Introduction to Protein Therapeutics
o 1.3.2 Therapeutic Applications
o 1.3.3 Market Size
o 1.3.4 Leading Product Classes
o 1.3.5 Leading Products
o 1.3.6 Market Share by Company
o 1.3.7 Innovation/R&D Trends
2 Challenges and Issues Facing the Therapeutic Protein Market
• 2.1 Pricing
• 2.2 Drug Delivery
o 2.2.1 Parenteral Delivery: Still the Leading Delivery Route for Therapeutic Proteins
o Case Study: Sustainable Release Injectable Technology
o 2.2.2 Pulmonary Delivery
o 2.2.3 Oral Delivery
• 2.3 Manufacturing Capacity
o Case Study: Immunex (Amgen) and Their Enbrel Shortage
o Case Study: Genentech
o 2.3.1 New Methods of Protein Manufacture
? 2.3.1.1 Transgenic Animal Production
? 2.3.1.2 Protein Pharming
? 2.3.1.3 Transgenic Plant Production
• 2.4 The Biogeneric Threat
o 2.4.1 Loss of Patent Protection
o 2.4.2 High Manufacturing Costs
o 2.4.3 Lack of Adequate Legislation
o Case Study: Biogenerics - Novartis and Omnitrope
o 2.4.4 Restrictive Cost of Biotech Generics
o 2.4.5 Biogeneric Landscape
3 Erythropoietins
• 3.1 Overview of Class
• 3.2 How Do Erythropoietins Work?
• 3.3 Therapeutic Applications for Erythropoietins
o 3.3.1 Anemia
? 3.3.1.1 Cancer Related Anemia
? 3.3.1.2 Renal Anemia
• 3.4 Currently Marketed Products in the Class
o 3.4.1 Procrit/Eprex (epoetin alfa)
o 3.4.2 Epogen (epoetin alfa)
o 3.4.3 Aranesp (darbepoetin alfa)
o 3.4.4 NeoRecormon/Epogin (epoetin beta)
o 3.4.5 Espo (epoetin alfa)
o 3.4.6 Clinical Comparisons Between Marketed Erythropoietins
• 3.5 Market Analysis
o 3.5.1 Commercial Market Size
o 3.5.2 Market Share by Country/Region
o 3.5.3 Market Share, by Product Sales
o 3.5.4 Market Share by Company
• 3.6 Key Emerging Erythropoietin Therapies
o 3.6.1 Dynepo
o 3.6.2 Mircera
• 3.7 Market Outlook
o 3.7.1 Drivers
o 3.7.2 Restraints
o 3.7.3 Financial Forecast
4 Interferons
• 4.1 Overview of Class
• 4.2 Therapeutic Uses for Interferons
o 4.2.1 Multiple Sclerosis
o 4.2.2 Hepatitis
o 4.2.3 Leukemia
• 4.3 Classes of Interferons
o 4.3.1 Beta Interferons
? 4.3.1.1 Avonex (interferon beta-1a)
? 4.3.1.2 Rebif (interferon beta-1a)
? 4.3.1.3 Betaferon/Betaseron (interferon beta-1b)
o 4.3.2 Alpha Interferons
? 4.3.2.1 Intron A (interferon alpha-2b)
? 4.3.2.2 PEG Intron (peg interferon alpha-2b)
? 4.3.2.3 Rebetron (interferon alpha-2b + ribavirin)
? 4.3.2.4 Roferon-A (interferon alpha-2a)
? 4.3.2.5 Alferon N (interferon alpha-n3)
? 4.3.2.6 Pegasys (pegylated interferon alpha-2a)
? 4.3.2.7 Infergen (interferon alfacon-1)
o 4.3.3 Gamma interferons
? 4.3.3.1 Actimmune
• 4.4 Market Analysis
o 4.4.1 Commercial Market Size
o 4.4.2 Market Share by Country/Region
o 4.4.3 Market Share by Product Sales
o 4.4.4 Market Share by Company
• 4.5 R&D Trends in the Interferon Class
o 4.5.1 Albuferon-Alpha
o 4.5.2 Tauferon
o 4.5.3 Interferon gamma-1b
o 4.5.4 Neoferon
o 4.5.5 Low-Dose Oral Interferon Alpha
• 4.6 Market Outlook
o 4.6.1 Drivers
o 4.6.2 Restraints
o 4.6.3 Financial Forecasts
? 4.6.3.1 Beta Interferon Financial Forecast
? 4.6.3.2 Alpha Interferon Financial Forecast
? 4.6.3.3 Gamma Interferon Financial Forecast
5 Insulins
• 5.1 Overview of Class
• 5.2 How Does Insulin Work?
• 5.3 Therapeutic Applications
• 5.3.1 Diabetes
• 5.4 Epidemiology
• 5.5 Key Products in Diabetes Treatment
o 5.5.1 Rapid-acting
? 5.5.1.1 NovoRapid/Novolog (insulin aspart)
? 5.5.1.2 Humalog (insulin lispro)
? 5.5.1.3 Apidra (insulin glulisine)
? 5.5.1.4 NovoMix (insulin aspart mix)
o 5.5.2 Exubera (inhaled insulin)
o 5.5.3 Short-acting (regular) and intermediate-acting
? 5.5.3.1 Novolin (insulin)
? 5.5.3.2 Insuman
? 5.5.3.3 Humulin (insulin)
o 5.5.4 Long-acting
? 5.5.4.1 Lantus (glargine insulin)
o 5.5.5 Levemir (insulin determir)
o 5.5.6 Iletin (insulin)
• 5.6 New Delivery of Insulin Stimulating Sales
• 5.7 R&D Trends
o 5.7.1 NN304 (insulin detemir)
o 5.7.2 AERx insulin Diabetes Management System (iDMS)
o 5.7.3 AIR (inhaled insulin)
o 5.7.4 MannKind (inhaled insulin)
o 5.7.5 NN344
o 5.7.6 NN5401
• 5.8 Market Analysis
o 5.8.1 Commercial Market Size
o 5.8.2 Market Share by Insulin Class
o 5.8.3 Market Share by Country/Region
o 5.8.4 Market Share by Product Sales
o 5.8.5 Market Share by Company
• 5.9 Market Outlook
o 5.9.1 Financial Forecast
o 5.9.2 Drivers
o 5.9.3 Restraints
6 Monoclonal Antibodies
• 6.1 Overview of Class
• 6.2 How do Monoclonal Antibodies Work?
• 6.3 Therapeutic Applications for Monoclonal Antibodies
o 6.3.1 Cancer
? 6.3.1.1 Rituxan (rituxumab)
? 6.3.1.2 Erbitux (cetuximab)
? 6.3.1.3 Herceptin (trastuzumab)
? 6.3.1.4 Avastin (bevacizumab)
? 6.3.1.5 Bexxar (tositumomab)
? 6.3.1.6 Mylotarg (gemtuzumab ozogamicin)
? 6.3.1.7 Zevalin (ibritumomab tiuxetan)
o 6.3.2 Autoimmune/Inflammatory Diseases
? 6.3.2.1 Rheumatoid Arthritis
? 6.3.2.1.1 Remicade (infliximab)
? 6.3.2.1.2 Humira (adalimumab)
? 6.3.2.2 Multiple Sclerosis
? 6.3.2.2.1 Tysabri (natalizumab)
? 6.3.2.3 Crohn' s Disease
? 6.3.2.3.1 Remicade
? 6.3.2.4 Psoriasis
? 6.3.2.4.1 Raptiva (efalizumab)
? 6.3.2.5 Asthma
? 6.3.2.5.1 Xolair
o 6.3.3 Age-Related Macular Degeneration (AMD)
? 6.3.3.1 Lucentis (ranibizumab)
o 6.3.4 Transplant Rejection
? 6.3.4.1 Simulect (basiliximab)
? 6.3.4.2 Orthoclone OKT-3 (muromonab CD3)
o 6.3.5 Other Conditions
? 6.3.5.1 Percutaneous coronary intervention (PCI)
? 6.3.5.1.1 ReoPro (abciximab)
? 6.3.5.2 Lower Respiratory Tract Disease
? 6.3.5.2.1 Synagis (palivizumab)
• 6.4 Market Analysis
o 6.4.1 Commercial Market Size
o 6.4.2 Segmentation by Therapeutic Category
? 6.4.2.1 Cancer
? 6.4.2.2 Autoimmune/Inflammatory
o 6.4.3 Market Share by Country/Region
o 6.4.4 Key Product Sales
o 6.4.5 Market Share by Company
o 6.4.6 Market Outlook
? 6.4.6.1 Drivers
? 6.4.6.2 Restraints
? 6.4.6.3 Financial Forecast
• 6.5 Emerging Monoclonal Antibody Therapies
o 6.5.1 Herceptin (Line Extension)
o 6.5.2 Cotara (TNT-1)
o 6.5.3 Rencarex (WX-G250)
o 6.5.4 Humira
o 6.5.5 Rituxan
o 6.5.6 Actemra (tocilizumab)
o 6.5.7 Remicade
o 6.5.8 Tysabri
o 6.5.9 Segard
o 6.5.10 Anti-C5 antibody
o 6.5.11 Aurograb
7 Blood-Clotting Factors
• 7.1 Overview of Class
• 7.2 How do Blood-Clotting Factors Work?
• 7.3 Therapeutic Applications for Blood-Clotting Factors
o 7.3.1 Hemophilia
• 7.4 Leading Blood-Clotting Factors on the Market
o 7.4.1 NovoSeven (recombinant coagulation factor VIIa)
o 7.4.2 Advate (antihemophilic factor (recombinant), plasma/albumin-free method)
o 7.4.3 Alphanate
o 7.4.4 Helixate FS
o 7.4.5 Hemofil-M (Factor VIII)
o 7.4.6 Humate-P (antihemophilic factor/von Willebrand factor complex)
o 7.4.7 Koate HP and Koate DVI (human antihemophilic (human) factor VIII)
o 7.4.8 Kogenate FS (recombinant factor VIII)
o 7.4.9 Monarc-M
o 7.4.10 Monoclate-P
o 7.4.11 Recombinate
o 7.4.12 ReFacto (recombinant factor VIII)
o 7.4.13 AlphaNine SD
o 7.4.14 Bebulin VH (factor IX complex)
o 7.4.15 BeneFIX (recombinant factor IX)
o 7.4.16 Konyne 80
o 7.4.17 Mononine
o 7.4.18 Profilnine SD (systemic factor IX)
o 7.4.19 Proplex T (factor IX complex)
• 7.5 Market Analysis
o 7.5.1 Commercial Market Size
o 7.5.2 Market Share by Country/Region
o 7.5.3 Market Share by Product Sales
o 7.5.4 Market Share by Company
o 7.5.5 Market Outlook
? 7.5.5.1 Drivers
? 7.5.5.2 Restraints
• 7.6 Emerging Blood-Clotting Factors
o 7.6.1 Bayer
o 7.6.2 Cell Genesys
o 7.6.3 Avigen
o 7.6.4 Novo Nordisk
o 7.6.5 Immune Response Corporation
o 7.6.6 Targeted Genetics
8 Colony-Stimulating Factors
• 8.1 Overview of Class
• 8.2 How Do Colony Stimulating Factors Work?
• 8.3 Therapeutic Applications for Colony Stimulating Factors
o 8.3.1 Chemotherapy-Induced Neutropenia
• 8.4 Key Colony Stimulating Factors
o 8.4.1 Neupogen (filgrastim)
o 8.4.2 Neulasta (pegfilgrastim)
o 8.4.3 Gran (filgrastim)
o 8.4.4 Leukine (sargramostim)
o 8.4.5 Neutrogin / Granocyte (lenograstim)
• 8.5 Market Analysis
o 8.5.1 Commercial Market Size
o 8.5.2 Market Share by Country/Region
o 8.5.3 Market Share by Product Sales
o 8.5.4 Market Share by Company
• 8.6 Market Outlook
o 8.6.1 Drivers
o 8.6.2 Restraints
o 8.6.3 Financial Forecast
• 8.7 Emerging Colony-Stimulating Factors
o 8.7.1 New Indications for Leukine (sargramostim)
o 8.7.2 Longer-acting GM-CSFs
o 8.7.3 PEGylated G-CSFs
o 8.7.4 Maxy-G34
9 Human Growth Hormones
• 9.1 Overview of Class
• 9.2 How Do Growth Hormones Work?
• 9.3 Therapeutic Applications for Growth Hormones
• 9.4 Key Growth Hormones
o 9.4.1 Genotropin (recombinant somatropin)
o 9.4.2 Nutropin/Protropin (recombinant somatropin/somatrem)
o 9.4.3 Norditropin/Norditropin SimpleXx (recombinant somatropin)
o 9.4.4 Humatrope (recombinant somatropin)
o 9.4.5 Geref (sermorelin acetate)
o 9.4.6 Somatuline (lanreotide)
o 9.4.7 Saizen (somatropin)
o 9.4.8 Serostim (recombinant somatropin)
o 9.4.9 Somavert (pegvisomant)
o 9.4.10 Sandostatin (octreotride) and Sandostatin LAR (octreotide for injectable suspension)
• 9.5 Expected Launches of Growth Hormones
o 9.5.1 Valtropin (somatropin)
o 9.5.2 Omnitrope (somatropin)
• 9.6 Market Analysis
o 9.6.1 Commercial Market Size
o 9.6.2 Segmentation by Therapeutic Category
o 9.6.3 Market Share by Country/Region
o 9.6.4 Market Share by Product Sales
o 9.6.5 Market Share by Company
• 9.7 Market Outlook
o 9.7.1 Drivers
o 9.7.2 Restraints
• 9.8 Emerging Human Growth Hormones
o 9.8.1 Serostim (Serono)
o 9.8.2 SomatoKine (Insmed Incorporated)
o 9.8.3 Octreotide (QLT)
o 9.8.4 ALX1-11 (NPS Pharmaceuticals)
o 9.8.5 Geref (Serono)
o 9.8.6 Leptin (Amgen)
o 9.8.7 hGH (SkyePharma)
o 9.8.8 hGHD-1 (Macromed)
10 Interleukins
• 10.1 Overview of Class
• 10.2 How Do Interleukins Work?
• 10.3 Types of Interleukins and Their Functions
• 10.4 Therapeutic Applications for Interleukins
o 10.4.1 Cancer
o 10.4.2 Human immunodeficiency virus (HIV)
o 10.4.3 Transplantation
• 10.5 Key Interleukin Products on Market
o 10.5.1 Interleukin-1
o 10.5.2 Interleukin-2
? 10.5.2.1 Proleukin (aldesleukin)
? 10.5.2.2 Ontak (denileukin deftitox)
? 10.5.2.3 Imunace (celmoleukin)
o 10.5.3 Interleukin 11
? 10.5.3.1 Neumega (oprelvekin)
• 10.6 Market Analysis
o 10.6.1 Commercial Market Size
o 10.6.2 Segmentation by Therapeutic Category
o 10.6.3 Market Share by Country/Region
o 10.6.4 Market Share by Product Sales
o 10.6.5 Market Share by Company
• 10.7 Market Outlook
o 10.7.1 Drivers
o 10.7.2 Restraints
• 10.8 Emerging Interleukins
o 10.8.1 IL-11 - Neumega (oprelvekin)
o 10.8.2 New Indication for Proleukin (aldesleukin)
o 10.8.3 Interleukin-12
o 10.8.4 Cytoryn (IL-2 controlled release injectable depot)
o 10.8.5 Interleukin-6 (Sigosix)
o 10.8.6 Interleukin-4
o 10.8.7 Interleukin-1
o 10.8.8 Recombinant IL-10
o 10.8.9 Prestara
11 Plasminogen Activators
• 11.1 Overview of Class
• 11.2 How Do Plasminogen Activators Work?
• 11.3 Therapeutic Applications for Plasminogen Activators
o 11.3.1 Heart Attack
o 11.3.2 Stroke
o 11.3.3 Pulmonary Embolism
• 11.4 Key Plasminogen Activators on Market
o 11.4.1 Activase (alteplase)
o 11.4.2 Actilyse (alteplase)
o 11.4.3 Abbokinase (urokinase)
o 11.4.4 Rapilysin/Retavase (reteplase)
o 11.4.5 TNKase (tenecteplase)
o 11.4.6 Metalyse (tenecteplase)
o 11.4.7 Streptase (streptokinase)
• 11.5 Market Analysis
o 11.5.1 Commercial Market Size
o 11.5.2 Segmentation by Therapeutic Category
o 11.5.3 Market Share by Country/Region
o 11.5.4 Market Share by Product Sales
o 11.5.5 Market Share by Company
• 11.6 Market Outlook
o 11.6.1 Drivers
o 11.6.2 Restraints
• 11.7 Emerging Plasminogen Activators
o 11.7.1 Solinase (pamiteplase)
o 11.7.2 Alfimeprase
o 11.7.3 Lanoteplase
12 Reproductive Hormones
• 12.1 Overview of Class
• 12.2 How do Reproductive Hormones Work?
• 12.3 Therapeutic Applications for Reproductive Hormones
o 12.3.1 Osteoporosis
o 12.3.2 Cancer
o 12.3.3 Menopause-Related Conditions
o 12.3.4 Male Sexual Dysfunctions
o 12.3.5 Infertility
o 12.3.6 Contraception
• 12.4 Leading Reproductive Hormones on the Market
o 12.4.1 Gonadotropins
o 12.4.2 Hormone Replacement Therapy
o 12.4.3 Estrogens and Progestins
• 12.5 Market Analysis
o 12.5.1 Commercial Market Size
o 12.5.2 Segmentation by Therapeutic Category
o 12.5.3 Market Share by Country/Region
o 12.5.4 Market Share by Product Sales
o 12.5.5 Market Share by Company
• 12.6 Market Outlook
o 12.6.1 Drivers
o 12.6.2 Restraints
• 12.7 Emerging Reproductive Hormones
13 Enzyme Replacement
• 13.1 Overview of Class
• 13.2 How does Enzyme Replacement Work?
• 13.3 Therapeutic Applications for Enzyme Replacement
o 13.3.1 Lysosomal storage disorders
o 13.3.2 Fabry Disease
o 13.3.3 Gaucher Disease
o 13.3.4 Mucopolysaccharidoses (MPSs)
o 13.3.5 Infantile Pompe Disease (IPD)
• 13.4 Leading Enzyme Replacement Therapies on the Market
o 13.4.1 Fabrazyme (agalsidase beta)
o 13.4.2 Ceredase (alglucerase)
o 13.4.3 Cerezyme (imiglucerase)
o 13.4.4 Myozyme (alglucosidase alfa)
o 13.4.5 Elaprase (idursulfase)
o 13.4.6 Naglazyme (galsulfase)
o 13.4.7 Aldurazyme (laronidase)
• 13.5 Market Analysis
o 13.5.1 Commercial Market Size
o 13.5.2 Segmentation by Therapeutic Category
o 13.5.3 Market Share by Country/Region
o 13.5.4 Market Share by Product Sales
o 13.5.5 Market Share by Company
• 13.6 Market Outlook
o 13.6.1 Drivers
o 13.6.2 Restraints
• 13.7 Emerging Enzyme Replacement Therapies
o 13.7.1 AGT-180
o 13.7.2 Phex
o 13.7.3 ENZAGAL
o 13.7.4 rhASB
14 Company Profiles
• 14.1 Abbott Laboratories
• 14.2 Amgen
• 14.3 Amylin Pharmaceuticals
• 14.4 Anika Therapeutics
• 14.5 ArmaGen Technologies
• 14.6 Biogen Idec
Table of Contents
1 Methodology, Executive Summary and Overview
• 1.1 Report Objectives
• 1.2 Research Methodology
• 1.3 Executive Summary
o 1.3.1 An Introduction to Protein Therapeutics
o 1.3.2 Therapeutic Applications
o 1.3.3 Market Size
o 1.3.4 Leading Product Classes
o 1.3.5 Leading Products
o 1.3.6 Market Share by Company
o 1.3.7 Innovation/R&D Trends
2 Challenges and Issues Facing the Therapeutic Protein Market
• 2.1 Pricing
• 2.2 Drug Delivery
o 2.2.1 Parenteral Delivery: Still the Leading Delivery Route for Therapeutic Proteins
o Case Study: Sustainable Release Injectable Technology
o 2.2.2 Pulmonary Delivery
o 2.2.3 Oral Delivery
• 2.3 Manufacturing Capacity
o Case Study: Immunex (Amgen) and Their Enbrel Shortage
o Case Study: Genentech
o 2.3.1 New Methods of Protein Manufacture
? 2.3.1.1 Transgenic Animal Production
? 2.3.1.2 Protein Pharming
? 2.3.1.3 Transgenic Plant Production
• 2.4 The Biogeneric Threat
o 2.4.1 Loss of Patent Protection
o 2.4.2 High Manufacturing Costs
o 2.4.3 Lack of Adequate Legislation
o Case Study: Biogenerics - Novartis and Omnitrope
o 2.4.4 Restrictive Cost of Biotech Generics
o 2.4.5 Biogeneric Landscape
3 Erythropoietins
• 3.1 Overview of Class
• 3.2 How Do Erythropoietins Work?
• 3.3 Therapeutic Applications for Erythropoietins
o 3.3.1 Anemia
? 3.3.1.1 Cancer Related Anemia
? 3.3.1.2 Renal Anemia
• 3.4 Currently Marketed Products in the Class
o 3.4.1 Procrit/Eprex (epoetin alfa)
o 3.4.2 Epogen (epoetin alfa)
o 3.4.3 Aranesp (darbepoetin alfa)
o 3.4.4 NeoRecormon/Epogin (epoetin beta)
o 3.4.5 Espo (epoetin alfa)
o 3.4.6 Clinical Comparisons Between Marketed Erythropoietins
• 3.5 Market Analysis
o 3.5.1 Commercial Market Size
o 3.5.2 Market Share by Country/Region
o 3.5.3 Market Share, by Product Sales
o 3.5.4 Market Share by Company
• 3.6 Key Emerging Erythropoietin Therapies
o 3.6.1 Dynepo
o 3.6.2 Mircera
• 3.7 Market Outlook
o 3.7.1 Drivers
o 3.7.2 Restraints
o 3.7.3 Financial Forecast
4 Interferons
• 4.1 Overview of Class
• 4.2 Therapeutic Uses for Interferons
o 4.2.1 Multiple Sclerosis
o 4.2.2 Hepatitis
o 4.2.3 Leukemia
• 4.3 Classes of Interferons
o 4.3.1 Beta Interferons
? 4.3.1.1 Avonex (interferon beta-1a)
? 4.3.1.2 Rebif (interferon beta-1a)
? 4.3.1.3 Betaferon/Betaseron (interferon beta-1b)
o 4.3.2 Alpha Interferons
? 4.3.2.1 Intron A (interferon alpha-2b)
? 4.3.2.2 PEG Intron (peg interferon alpha-2b)
? 4.3.2.3 Rebetron (interferon alpha-2b + ribavirin)
? 4.3.2.4 Roferon-A (interferon alpha-2a)
? 4.3.2.5 Alferon N (interferon alpha-n3)
? 4.3.2.6 Pegasys (pegylated interferon alpha-2a)
? 4.3.2.7 Infergen (interferon alfacon-1)
o 4.3.3 Gamma interferons
? 4.3.3.1 Actimmune
• 4.4 Market Analysis
o 4.4.1 Commercial Market Size
o 4.4.2 Market Share by Country/Region
o 4.4.3 Market Share by Product Sales
o 4.4.4 Market Share by Company
• 4.5 R&D Trends in the Interferon Class
o 4.5.1 Albuferon-Alpha
o 4.5.2 Tauferon
o 4.5.3 Interferon gamma-1b
o 4.5.4 Neoferon
o 4.5.5 Low-Dose Oral Interferon Alpha
• 4.6 Market Outlook
o 4.6.1 Drivers
o 4.6.2 Restraints
o 4.6.3 Financial Forecasts
? 4.6.3.1 Beta Interferon Financial Forecast
? 4.6.3.2 Alpha Interferon Financial Forecast
? 4.6.3.3 Gamma Interferon Financial Forecast
5 Insulins
• 5.1 Overview of Class
• 5.2 How Does Insulin Work?
• 5.3 Therapeutic Applications
• 5.3.1 Diabetes
• 5.4 Epidemiology
• 5.5 Key Products in Diabetes Treatment
o 5.5.1 Rapid-acting
? 5.5.1.1 NovoRapid/Novolog (insulin aspart)
? 5.5.1.2 Humalog (insulin lispro)
? 5.5.1.3 Apidra (insulin glulisine)
? 5.5.1.4 NovoMix (insulin aspart mix)
o 5.5.2 Exubera (inhaled insulin)
o 5.5.3 Short-acting (regular) and intermediate-acting
? 5.5.3.1 Novolin (insulin)
? 5.5.3.2 Insuman
? 5.5.3.3 Humulin (insulin)
o 5.5.4 Long-acting
? 5.5.4.1 Lantus (glargine insulin)
o 5.5.5 Levemir (insulin determir)
o 5.5.6 Iletin (insulin)
• 5.6 New Delivery of Insulin Stimulating Sales
• 5.7 R&D Trends
o 5.7.1 NN304 (insulin detemir)
o 5.7.2 AERx insulin Diabetes Management System (iDMS)
o 5.7.3 AIR (inhaled insulin)
o 5.7.4 MannKind (inhaled insulin)
o 5.7.5 NN344
o 5.7.6 NN5401
• 5.8 Market Analysis
o 5.8.1 Commercial Market Size
o 5.8.2 Market Share by Insulin Class
o 5.8.3 Market Share by Country/Region
o 5.8.4 Market Share by Product Sales
o 5.8.5 Market Share by Company
• 5.9 Market Outlook
o 5.9.1 Financial Forecast
o 5.9.2 Drivers
o 5.9.3 Restraints
6 Monoclonal Antibodies
• 6.1 Overview of Class
• 6.2 How do Monoclonal Antibodies Work?
• 6.3 Therapeutic Applications for Monoclonal Antibodies
o 6.3.1 Cancer
? 6.3.1.1 Rituxan (rituxumab)
? 6.3.1.2 Erbitux (cetuximab)
? 6.3.1.3 Herceptin (trastuzumab)
? 6.3.1.4 Avastin (bevacizumab)
? 6.3.1.5 Bexxar (tositumomab)
? 6.3.1.6 Mylotarg (gemtuzumab ozogamicin)
? 6.3.1.7 Zevalin (ibritumomab tiuxetan)
o 6.3.2 Autoimmune/Inflammatory Diseases
? 6.3.2.1 Rheumatoid Arthritis
? 6.3.2.1.1 Remicade (infliximab)
? 6.3.2.1.2 Humira (adalimumab)
? 6.3.2.2 Multiple Sclerosis
? 6.3.2.2.1 Tysabri (natalizumab)
? 6.3.2.3 Crohn' s Disease
? 6.3.2.3.1 Remicade
? 6.3.2.4 Psoriasis
? 6.3.2.4.1 Raptiva (efalizumab)
? 6.3.2.5 Asthma
? 6.3.2.5.1 Xolair
o 6.3.3 Age-Related Macular Degeneration (AMD)
? 6.3.3.1 Lucentis (ranibizumab)
o 6.3.4 Transplant Rejection
? 6.3.4.1 Simulect (basiliximab)
? 6.3.4.2 Orthoclone OKT-3 (muromonab CD3)
o 6.3.5 Other Conditions
? 6.3.5.1 Percutaneous coronary intervention (PCI)
? 6.3.5.1.1 ReoPro (abciximab)
? 6.3.5.2 Lower Respiratory Tract Disease
? 6.3.5.2.1 Synagis (palivizumab)
• 6.4 Market Analysis
o 6.4.1 Commercial Market Size
o 6.4.2 Segmentation by Therapeutic Category
? 6.4.2.1 Cancer
? 6.4.2.2 Autoimmune/Inflammatory
o 6.4.3 Market Share by Country/Region
o 6.4.4 Key Product Sales
o 6.4.5 Market Share by Company
o 6.4.6 Market Outlook
? 6.4.6.1 Drivers
? 6.4.6.2 Restraints
? 6.4.6.3 Financial Forecast
• 6.5 Emerging Monoclonal Antibody Therapies
o 6.5.1 Herceptin (Line Extension)
o 6.5.2 Cotara (TNT-1)
o 6.5.3 Rencarex (WX-G250)
o 6.5.4 Humira
o 6.5.5 Rituxan
o 6.5.6 Actemra (tocilizumab)
o 6.5.7 Remicade
o 6.5.8 Tysabri
o 6.5.9 Segard
o 6.5.10 Anti-C5 antibody
o 6.5.11 Aurograb
7 Blood-Clotting Factors
• 7.1 Overview of Class
• 7.2 How do Blood-Clotting Factors Work?
• 7.3 Therapeutic Applications for Blood-Clotting Factors
o 7.3.1 Hemophilia
• 7.4 Leading Blood-Clotting Factors on the Market
o 7.4.1 NovoSeven (recombinant coagulation factor VIIa)
o 7.4.2 Advate (antihemophilic factor (recombinant), plasma/albumin-free method)
o 7.4.3 Alphanate
o 7.4.4 Helixate FS
o 7.4.5 Hemofil-M (Factor VIII)
o 7.4.6 Humate-P (antihemophilic factor/von Willebrand factor complex)
o 7.4.7 Koate HP and Koate DVI (human antihemophilic (human) factor VIII)
o 7.4.8 Kogenate FS (recombinant factor VIII)
o 7.4.9 Monarc-M
o 7.4.10 Monoclate-P
o 7.4.11 Recombinate
o 7.4.12 ReFacto (recombinant factor VIII)
o 7.4.13 AlphaNine SD
o 7.4.14 Bebulin VH (factor IX complex)
o 7.4.15 BeneFIX (recombinant factor IX)
o 7.4.16 Konyne 80
o 7.4.17 Mononine
o 7.4.18 Profilnine SD (systemic factor IX)
o 7.4.19 Proplex T (factor IX complex)
• 7.5 Market Analysis
o 7.5.1 Commercial Market Size
o 7.5.2 Market Share by Country/Region
o 7.5.3 Market Share by Product Sales
o 7.5.4 Market Share by Company
o 7.5.5 Market Outlook
? 7.5.5.1 Drivers
? 7.5.5.2 Restraints
• 7.6 Emerging Blood-Clotting Factors
o 7.6.1 Bayer
o 7.6.2 Cell Genesys
o 7.6.3 Avigen
o 7.6.4 Novo Nordisk
o 7.6.5 Immune Response Corporation
o 7.6.6 Targeted Genetics
8 Colony-Stimulating Factors
• 8.1 Overview of Class
• 8.2 How Do Colony Stimulating Factors Work?
• 8.3 Therapeutic Applications for Colony Stimulating Factors
o 8.3.1 Chemotherapy-Induced Neutropenia
• 8.4 Key Colony Stimulating Factors
o 8.4.1 Neupogen (filgrastim)
o 8.4.2 Neulasta (pegfilgrastim)
o 8.4.3 Gran (filgrastim)
o 8.4.4 Leukine (sargramostim)
o 8.4.5 Neutrogin / Granocyte (lenograstim)
• 8.5 Market Analysis
o 8.5.1 Commercial Market Size
o 8.5.2 Market Share by Country/Region
o 8.5.3 Market Share by Product Sales
o 8.5.4 Market Share by Company
• 8.6 Market Outlook
o 8.6.1 Drivers
o 8.6.2 Restraints
o 8.6.3 Financial Forecast
• 8.7 Emerging Colony-Stimulating Factors
o 8.7.1 New Indications for Leukine (sargramostim)
o 8.7.2 Longer-acting GM-CSFs
o 8.7.3 PEGylated G-CSFs
o 8.7.4 Maxy-G34
9 Human Growth Hormones
• 9.1 Overview of Class
• 9.2 How Do Growth Hormones Work?
• 9.3 Therapeutic Applications for Growth Hormones
• 9.4 Key Growth Hormones
o 9.4.1 Genotropin (recombinant somatropin)
o 9.4.2 Nutropin/Protropin (recombinant somatropin/somatrem)
o 9.4.3 Norditropin/Norditropin SimpleXx (recombinant somatropin)
o 9.4.4 Humatrope (recombinant somatropin)
o 9.4.5 Geref (sermorelin acetate)
o 9.4.6 Somatuline (lanreotide)
o 9.4.7 Saizen (somatropin)
o 9.4.8 Serostim (recombinant somatropin)
o 9.4.9 Somavert (pegvisomant)
o 9.4.10 Sandostatin (octreotride) and Sandostatin LAR (octreotide for injectable suspension)
• 9.5 Expected Launches of Growth Hormones
o 9.5.1 Valtropin (somatropin)
o 9.5.2 Omnitrope (somatropin)
• 9.6 Market Analysis
o 9.6.1 Commercial Market Size
o 9.6.2 Segmentation by Therapeutic Category
o 9.6.3 Market Share by Country/Region
o 9.6.4 Market Share by Product Sales
o 9.6.5 Market Share by Company
• 9.7 Market Outlook
o 9.7.1 Drivers
o 9.7.2 Restraints
• 9.8 Emerging Human Growth Hormones
o 9.8.1 Serostim (Serono)
o 9.8.2 SomatoKine (Insmed Incorporated)
o 9.8.3 Octreotide (QLT)
o 9.8.4 ALX1-11 (NPS Pharmaceuticals)
o 9.8.5 Geref (Serono)
o 9.8.6 Leptin (Amgen)
o 9.8.7 hGH (SkyePharma)
o 9.8.8 hGHD-1 (Macromed)
10 Interleukins
• 10.1 Overview of Class
• 10.2 How Do Interleukins Work?
• 10.3 Types of Interleukins and Their Functions
• 10.4 Therapeutic Applications for Interleukins
o 10.4.1 Cancer
o 10.4.2 Human immunodeficiency virus (HIV)
o 10.4.3 Transplantation
• 10.5 Key Interleukin Products on Market
o 10.5.1 Interleukin-1
o 10.5.2 Interleukin-2
? 10.5.2.1 Proleukin (aldesleukin)
? 10.5.2.2 Ontak (denileukin deftitox)
? 10.5.2.3 Imunace (celmoleukin)
o 10.5.3 Interleukin 11
? 10.5.3.1 Neumega (oprelvekin)
• 10.6 Market Analysis
o 10.6.1 Commercial Market Size
o 10.6.2 Segmentation by Therapeutic Category
o 10.6.3 Market Share by Country/Region
o 10.6.4 Market Share by Product Sales
o 10.6.5 Market Share by Company
• 10.7 Market Outlook
o 10.7.1 Drivers
o 10.7.2 Restraints
• 10.8 Emerging Interleukins
o 10.8.1 IL-11 - Neumega (oprelvekin)
o 10.8.2 New Indication for Proleukin (aldesleukin)
o 10.8.3 Interleukin-12
o 10.8.4 Cytoryn (IL-2 controlled release injectable depot)
o 10.8.5 Interleukin-6 (Sigosix)
o 10.8.6 Interleukin-4
o 10.8.7 Interleukin-1
o 10.8.8 Recombinant IL-10
o 10.8.9 Prestara
11 Plasminogen Activators
• 11.1 Overview of Class
• 11.2 How Do Plasminogen Activators Work?
• 11.3 Therapeutic Applications for Plasminogen Activators
o 11.3.1 Heart Attack
o 11.3.2 Stroke
o 11.3.3 Pulmonary Embolism
• 11.4 Key Plasminogen Activators on Market
o 11.4.1 Activase (alteplase)
o 11.4.2 Actilyse (alteplase)
o 11.4.3 Abbokinase (urokinase)
o 11.4.4 Rapilysin/Retavase (reteplase)
o 11.4.5 TNKase (tenecteplase)
o 11.4.6 Metalyse (tenecteplase)
o 11.4.7 Streptase (streptokinase)
• 11.5 Market Analysis
o 11.5.1 Commercial Market Size
o 11.5.2 Segmentation by Therapeutic Category
o 11.5.3 Market Share by Country/Region
o 11.5.4 Market Share by Product Sales
o 11.5.5 Market Share by Company
• 11.6 Market Outlook
o 11.6.1 Drivers
o 11.6.2 Restraints
• 11.7 Emerging Plasminogen Activators
o 11.7.1 Solinase (pamiteplase)
o 11.7.2 Alfimeprase
o 11.7.3 Lanoteplase
12 Reproductive Hormones
• 12.1 Overview of Class
• 12.2 How do Reproductive Hormones Work?
• 12.3 Therapeutic Applications for Reproductive Hormones
o 12.3.1 Osteoporosis
o 12.3.2 Cancer
o 12.3.3 Menopause-Related Conditions
o 12.3.4 Male Sexual Dysfunctions
o 12.3.5 Infertility
o 12.3.6 Contraception
• 12.4 Leading Reproductive Hormones on the Market
o 12.4.1 Gonadotropins
o 12.4.2 Hormone Replacement Therapy
o 12.4.3 Estrogens and Progestins
• 12.5 Market Analysis
o 12.5.1 Commercial Market Size
o 12.5.2 Segmentation by Therapeutic Category
o 12.5.3 Market Share by Country/Region
o 12.5.4 Market Share by Product Sales
o 12.5.5 Market Share by Company
• 12.6 Market Outlook
o 12.6.1 Drivers
o 12.6.2 Restraints
• 12.7 Emerging Reproductive Hormones
13 Enzyme Replacement
• 13.1 Overview of Class
• 13.2 How does Enzyme Replacement Work?
• 13.3 Therapeutic Applications for Enzyme Replacement
o 13.3.1 Lysosomal storage disorders
o 13.3.2 Fabry Disease
o 13.3.3 Gaucher Disease
o 13.3.4 Mucopolysaccharidoses (MPSs)
o 13.3.5 Infantile Pompe Disease (IPD)
• 13.4 Leading Enzyme Replacement Therapies on the Market
o 13.4.1 Fabrazyme (agalsidase beta)
o 13.4.2 Ceredase (alglucerase)
o 13.4.3 Cerezyme (imiglucerase)
o 13.4.4 Myozyme (alglucosidase alfa)
o 13.4.5 Elaprase (idursulfase)
o 13.4.6 Naglazyme (galsulfase)
o 13.4.7 Aldurazyme (laronidase)
• 13.5 Market Analysis
o 13.5.1 Commercial Market Size
o 13.5.2 Segmentation by Therapeutic Category
o 13.5.3 Market Share by Country/Region
o 13.5.4 Market Share by Product Sales
o 13.5.5 Market Share by Company
• 13.6 Market Outlook
o 13.6.1 Drivers
o 13.6.2 Restraints
• 13.7 Emerging Enzyme Replacement Therapies
o 13.7.1 AGT-180
o 13.7.2 Phex
o 13.7.3 ENZAGAL
o 13.7.4 rhASB
14 Company Profiles
• 14.1 Abbott Laboratories
• 14.2 Amgen
• 14.3 Amylin Pharmaceuticals
• 14.4 Anika Therapeutics
• 14.5 ArmaGen Technologies
• 14.6 Biogen Idec
• 14.7 BioMarin Pharmaceutical
• 14.8 BioMimetic Therapeutics
• 14.9 Bolder BioTechnology
• 14.10 Boston Life Sciences
• 14.11 Cambrex
• 14.12 Cambridge Antibody Technology
• 14.13 Ceregene
• 14.14 Chiron Corporation
• 14.15 Chugai Pharmaceutical
• 14.16 Coley Pharmaceutical Group
• 14.17 CuraGen
• 14.18 Curis Inc
• 14.19 Dragon Pharmaceuticals
• 14.20 Enobia
• 14.21 Enzon
• 14.22 Eyetech Pharmaceuticals
• 14.23 FibroGen
• 14.24 FzioMed
• 14.25 GeneMedix
• 14.26 Genentech
• 14.27 Genmab
• 14.28 GenSci Regeneration Sciences
• 14.29 Genvec
• 14.30 Genzyme
• 14.31 Human Genome Sciences
• 14.32 ImClone Systems
• 14.33 Insmed
• 14.34 Janssen-Ortho
• 14.35 Johnson & Johnson
• 14.36 Maxygen
• 14.37 Medarex
• 14.38 MedImmune
• 14.39 OSI Pharmaceuticals
• 14.40 PeproTech
• 14.41 PDL Biopharma
• 14.42 Protein Polymer Technology
• 14.43 Raven Biotechnologies
• 14.44 Regeneron Pharmaceuticals
• 14.45 Rentschler Biotechnologie
• 14.46 Roche
• 14.47 Sangamo Biosciences
• 14.48 Scil Proteins
• 14.49 Serono
• 14.50 Spectrum Pharmaceuticals
• 14.51 Seattle Genetics
• 14.52 Stryker Biotech
• 14.53 Theratechnologies
• 14.54 Transition Therapeutics
• 14.55 Vernalis Pharmaceuticals
• 14.56 Wockhardt
• 14.57 Wyeth
• 14.58 Xoma
• 14.59 ZymoGenetics
Tables
• Table 1.1 Key Therapeutic Applications by Protein Class
• Table 1.2 Leading Product Classes in Protein Therapeutics
• Table 1.3 Leading Products in the Protein Therapeutics Market
• Table 1.4 Leading 20 Companies in Protein Therapeutics by 2005 Sales
• Table 2.1 Main Types of Drug Delivery by Injection (Parenteral Administration)
• Table 2.2 Advantages of Injectable Drug Delivery Systems
• Table 2.3 Key Companies in the Needleless Drug Technology Market
• Table 2.4 Companies Involved in the Field of Transgenic Protein Technology
• Table 2.5 Main Methods of Creating Transgenic Animals
• Table 2.6 Advantages of Avian Transgenic Technology in Protein Manufacture
• Table 2.7 Pros and Cons of Transgenic Plants
• Table 3.1 Advantages and Disadvantage of Erythropoietin Therapy
• Table 3.2 Global Sales of Erythropoietins 1999-2005
• Table 3.3 US Sales of Erythropoietins 1999-2005
• Table 3.4 Non-US Sales of Erythropoietins 1999-2005
• Table 3.5 Erythropoietin Financial Forecast 2005-2011
• Table 4.1 Major Types of MS
• Table 4.2 Major Types of Leukemia
• Table 4.3 Types of Leukemia Treatments
• Table 4.4 Leading MS Therapy Delivery Routes and Dosage
• Table 4.5 Global Sales of Beta Interferons 2000-2005
• Table 4.6 US Sales of Beta Interferons 2000-2005
• Table 4.7 Non-US Sales of Beta Interferons 2000-2005
• Table 4.8 Global Sales of Alpha Interferons 2000-2005
• Table 4.9 Global Sales of Gamma Interferons 2000-2005
• Table 4.10 Forecast Sales of Avonex
• Table 4.11 Forecast Sales of Betaseron
• Table 4.12 Forecast Sales of Rebif
• Table 4.13 Forecast Sales of PEG-Intron
• Table 4.14 Forecast Sales of Intron
• Table 4.15 Forecast Sales of Pegasys
• Table 4.16 Forecast Sales of Actimmune
• Table 5.1 Other Types of Diabetes
• Table 5.2 Treatment of Types II Diabetes
• Table 5.3 Estimated Number of People with Diabetes
• Table 5.4 Types of Insulin
• Table 5.5 Relationship of A1C to Average Whole Blood and Plasma Glucose Levels
• Table 5.6 Patch Insulin
• Table 5.7 Oral Spray Insulin
• Table 5.8 Pulmonary Insulin
• Table 5.9 Insulin Product Sales (US$mn)
• Table 5.10 Forecast Insulin Product Sales
• Table 5.11 Financial Forecast for the Insulin Market
• Table 6.1 Monoclonal Antibody Therapies on the Market 2006
• Table 6.2 Types of Cancer
• Table 6.3 Types of Transplant Rejection
• Table 6.4 Antibodies Used to Prevent Transplant Rejection
• Table 6.5 Leading Monoclonal Antibody Products, by Sales 2000-2005
• Table 6.6 Global Sales of Monoclonal Antibodies, Cancer Indications 2003-2005
• Table 6.7 Global Sales of Monoclonal Antibodies, Autoimmune/Inflammatory Indications, 1999-2005
• Table 6.8 Monoclonal Antibody Sales Market Share (2005), by Country/Region
• Table 6.9 Global Sales of Remicade 2000-2005
• Table 6.10 Global Sales of Rituxan 2000-2005
• Table 6.11 Global Sales of Herceptin 2000-2005
• Table 6.12 Global Sales of Humira 2003-2005
• Table 6.13 Global Sales of Avastin 2004-2005
• Table 6.14 Financial Forecast for the Monoclonal Antibody Market
• Table 6.15 Emerging Monoclonal Antibody Therapies
• Table 6.16 Types of ACR Response Criteria
• Table 7.1 Overview of Blood-Clotting Factors and Their Function
• Table 7.2 Leading Blood-Clotting Factors
• Table 7.3 Competing Antihemophilic Factor Brands
• Table 7.4 Key Blood Clotting Factors Product Sales (US$mn)
• Table 7.5 Forecast Sales of Blood Clotting Factors (US$bn)
• Table 8.1 Global Sales of Neupogen 1999-2005
• Table 8.2 Global Sales of Neulasta 2002-2005
• Table 8.3 Forecast Sales of Neulasta
• Table 8.4 Forecast Sales of Neupogen
• Table 8.5 Forecast Sales of Colony Stimulating Factors (US$bn)
• Table 9.1 Effects of Human Growth Hormone
• Table 9.2 Therapeutic Applications for Growth Hormones
• Table 9.3 Different Indications for Genotropin
• Table 9.4 GH Suppression during Long-Term Treatment with Immediate Release Sandostatin Injection and Sandostatin LAR Depot
• Table 9.5 Global Sales of Key Growth Hormone Products (US$mn)
• Table 9.6 Key Company Involvement in hGH Delivery Technology
• Table 9.7 Forecast Sales of Growth Hormones (US$bn)
• Table 10.1 Interleukins, Major Sources and Effects
• Table 10.2 Global Sales of Key Interleukins
• Table 10.3 Forecast Sales of Interleukins (US$mn)
• Table 11.1 Embolism and Its Outcomes
• Table 11.2 Brand Names of PAs
• Table 11.3 Forecast Sales of Plasminogen Activators
• Table 12.1 Overview of Reproductive Hormones
• Table 12.2 Reproductive Hormones and Their Therapeutic Applications
• Table 12.3 FDA-Approved Bisphosphonates for the Treatment of Osteoporosis in Post-Menopausal Women
• Table 12.4 Incidence and Death Rates of Cancer in the US (Male and Female)
• Table 12.5 Hormone Therapy Regimes
• Table 12.6 Medications for the Treatment of Infertility
• Table 12.7 FDA-Approved Estrogens/Hormones for the Treatment of Osteoporosis
• Table 12.8 Sales of Key Gonadotropins in US 2003-2005 (US$mn)
• Table 12.9 Global Sales of Key HRT Products in US$mn (2003-2005)
• Table 12.10 Global Sales of Johnson & Johnson' s Hormonal Contraceptives in US$mn (2003-2005)
• Table 12.11 Global Sales of Schering AG' s Hormonal Contraceptives in US$mn (2004-2005)
• Table 12.12 Forecast Sales of Reproductive Hormones
• Table 13.1 Types of Mucopolysaccharidosis
• Table 13.2 Global Sales of Key Enzyme Replacement Products
• Table 13.3 Key Companies Involved in the ERT Market
• Table 14.1 Biogen Idec' s Oncology Pipeline
• Table 14.2 Chiron' s Oncology Pipeline
• Table 14.3 Chugai' s Oncology Pipeline
• Table 14.4 Enzon Drug Delivery Portfolio, 2006
• Table 14.7 Wockhardt' s Biopharmaceutical Pipeline
• Table 14.5 Medarex' s Oncology Pipeline
Graphs
• Graph 1.1 Market Share of Product Classes in Protein Therapeutics
• Graph 1.2 Percentage Change in the 2005-2010 Sales of Protein Therapeutics by Class
• Graph 1.3 Leading 10 Products in the Protein Therapeutics Market by 2005 Sales
• Graph 1.4 Protein Therapeutics Market Share by Company
• Graph 3.1 Sales of Erythropoietin Products 1999-2005, US & Rest of World
• Graph 3.2 Percentage Growth of Erythropoietin Products, 2004-2005
• Graph 3.3 Market Share Erythropoietin Products, US vs Rest of World 2005
• Graph 3.4 Market Share Erythropoietin Products, US vs Rest of World 2004
• Graph 3.5 Market Share, Erythropoietin Products 2005
• Graph 3.6 Market Share, Erythropoietin Products 2004
• Graph 3.7 Company Market Share, Erythropoietin Products 2005
• Graph 3.8 Company Market Share, Erythropoietin Products 2004
• Graph 4.1 2005 Sales of Leading MS Therapies
• Graph 4.2 Country/Region Market Share Beta Interferons 2005
• Graph 4.3 Market Share Beta Interferons 2005
• Graph 4.4 Market Share Alpha Interferons 2005
• Graph 4.5 Company Market Share, Beta Interferons 2005
• Graph 4.6 Company Market Share Alpha Interferons 2005
• Graph 5.1 Insulin Sales Segmentation by Drug Class
• Graph 5.2 Insulin Market by Country/Region
• Graph 5.3 Humulin Sales by Geographical Region (2005)
• Graph 5.4 Humalog Sales by Geographical Region (2005)
• Graph 5.5 Insulin Market Share by Product (2005)
• Graph 5.6 Insulin Market Share by Company
• Graph 5.7 Product Sales Percentage Change 2005-2010*
• Graph 5.8 Forecast Growth of the Insulin Market (2005-2010)
• Graph 6.1 Leading Monoclonal Antibody Products by 2005 Sales
• Graph 6.2 Monoclonal Antibody Market by Therapeutic Category (2005)
• Graph 6.3 Annual Growth of Global Monoclonal Antibody Market, Cancer Indications 2003-2005
• Graph 6.4 Annual Growth of Global Monoclonal Antibody Market, Autoimmune/Inflammatory Indications, 1999-2005
• Graph 6.5 Monoclonal Antibody Sales Market Share by Three Key Regions
• Graph 6.6 Monoclonal Antibody Market Share, by Top Five Products
• Graph 6.11 Leaders in the Monoclonal Antibody Therapy Market, 2005 Market Share
• Graph 7.1 Blood Clotting Market Share by Country/Region
• Graph 7.2 Blood Clotting Market Share by Factor
• Graph 7.3 Blood Clotting Market Share by Company
• Graph 7.4 Forecast Annual Growth of Blood Clotting Factors
• Graph 8.1 CSF Market by Country/Region
• Graph 8.2 Global Sales of Neupogen and Neulasta 2002-2005
• Graph 8.3 Global CSF Market by Product (2005)
• Graph 8.4 Global CSF Market by Company (2005)
• Graph 8.5 Forecast Annual Sales Growth of the CSF Market
• Graph 9.1 HGH Market Segmentation by Therapeutic Application
• Graph 9.2 HGH Market by Region (2005)
• Graph 9.3 Growth Hormone Market Share by Company
• Graph 9.4 Forecast Annual Growth of Growth Hormones
• Graph 10.1 Interleukin Market Segmentation by Therapeutic Category
• Graph 10.2 Interleukin Market Segmentation by Country/Region
• Graph 10.3 Interleukins Market by Product Sales
• Graph 10.4 Market Share by Company
• Graph 10.5 Forecast Annual Sales Growth of Interleukins
• Graph 11.1 Plasminogen Activators Market Share by Therapeutic Application
• Graph 11.2 Plasminogen Activators Market Segmentation by Country/Region
• Graph 11.3 Plasminogen Activators Market Share by Product Sales
• Graph 11.4 Global Sales of Genentech' s PAs (US$mn)*
• Graph 11.5 Plasminogen Activators Market Share by Company
• Graph 11.6 Forecast Annual Sales Growth of Plasminogen Activators
• Graph 12.1 Segmentation of Hormone Replacement Market by Therapeutic Category
• Graph 12.2 Reproductive Hormones Market Segmentation by Country/Region
• Graph 12.3 Global Sales of Key Gonadotropins
• Graph 12.4 Annual Growth of HRT Product Sales
• Graph 12.5 Forecast Annual Sales Growth of Reproductive Hormones
• Graph 13.1 ERT Market Segmentation by Therapeutic Category
• Graph 13.2 ERT Market Segmentation by Country/Region
• Graph 13.3 Global Sales of Key Enzyme Replacement Products
• Graph 13.4 ERT Market by Company
Figures
• Figure 12.1 Simplified Graphic Representation of Normal Gonadal Function